文献速递银屑病与炎症性皮肤病

有效生物制剂治疗下银屑病残留斑块仍持续存在炎症表型

Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy.
PubMed 文献 · J Invest Dermatol · 2019-11-09

研究比较50例受试者(三种生物制剂治疗后残留斑块患者、未治疗患者及健康对照)的皮肤活检,采用mRNA表达、组织学和流式细胞术分析。结果显示治疗斑块中关键银屑病通路持续存在,包括粒细胞黏附与血细胞渗出、Th17活化通路和干扰素信号,且抗TNF增加干扰素信号通路;肥大细胞是所有银屑病患者IL-22的主要来源。

要点

  • 生物制剂治疗后的残留斑块仍持续表达关键银屑病炎症通路。
  • 抗TNF治疗可增加已存在的干扰素信号通路。
  • 肥大细胞是所有银屑病患者IL-22的主要来源。

核心结论

  • 生物制剂治疗后的残留斑块虽可见细微差异,但 underlying 生物学机制与未治疗银屑病皮损相似。

研究设计与样本

  • 研究纳入50例受试者,包括接受三种不同生物制剂之一治疗的残留斑块银屑病患者、未治疗患者和健康对照。
  • 对所有受试者皮肤活检采用mRNA表达、组织学和流式细胞术三种方法分析造血皮肤细胞。

主要发现

  • 三种方法均提供药物效应证据,但基因表达分析显示治疗斑块中关键银屑病通路持续存在,包括粒细胞黏附与血细胞渗出、Th17活化通路和干扰素信号,无新通路出现。
  • 观察到角化不全和角质形成细胞增殖局灶性减少,以及产生IL-17的CD103- T细胞差异性减少,但CD103+组织驻留记忆T细胞无变化。
  • 抗TNF增加了已存在的干扰素信号通路。
  • 肥大细胞是所有银屑病患者IL-22的主要来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many psoriasis patients treated with biologics do not achieve total skin clearance. These patients possess residual plaques despite ongoing biologic treatment. To elucidate mechanisms of plaque persistence despite overall good drug response, we studied 50 subjects: psoriasis patients with residual plaques treated with one of three different biologics, untreated patients, and healthy controls. Skin biopsies from all subjects were characterized using three methods: mRNA expression, histology, and FACS of hematopoietic skin cells. Although all three methods provided evidence of drug effect, gene expression analysis revealed the persistence of key psoriasis pathways in treated plaques, including granulocyte adhesion and diapedesis, T helper type17 activation pathway, and interferon signaling with no novel pathways emerging. Focal decreases in parakeratosis and keratinocyte proliferation and differential reduction in IL-17 producing CD103- T cells, but no change in CD103+ tissue-resident memory T cells were observed. Of note, antitumor necrosis factor increased the interferon signaling pathway already present. Interestingly mast cells were the dominant source of IL-22 in all psoriasis subjects. These data suggest that while subtle differences can be observed in drug-treated plaques, underlying biologic mechanisms are similar to those present in untreated psoriatic lesions.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Mashiko S, Edelmayer RM, Bi Y, et al. Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy. J Invest Dermatol. 2019. PMID: 31715177. doi:10.1016/j.jid.2019.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。